Supplementary Data — Ibuzatrelvir for COVID-19: real-time meta analysis of 1 study

@CovidAnalysis, November 2025, Version 1V1
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Mortezavi (DB RCT) 27% 0.73 [0.62-0.85] viral load 66 (n) 60 (n) Improvement, RR [CI] Treatment Control Mortezavi (DB RCT) 20% 0.80 [0.67-0.95] viral load 24 (n) 60 (n) Mortezavi (DB RCT) 18% 0.82 [0.70-0.97] viral load 34 (n) 60 (n) Mortezavi (DB RCT) 48% 0.52 [0.38-0.72] viral load 70 (n) 63 (n) Mortezavi (DB RCT) 48% 0.52 [0.37-0.74] viral load 27 (n) 63 (n) Mortezavi (DB RCT) 35% 0.65 [0.46-0.92] viral load 35 (n) 63 (n) Ibuzatrelvir COVID-19 outcomes c19early.org November 2025 Favors ibuzatrelvir Favors control
Fig. S1. All outcomes.
Loading..
Fig. S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.